Objectives. To determine if urate-lowering treatment (ULT) in gout can reduce cardiovascular (CV) outcomes.
Introduction
Gout is a common inflammatory arthropathy characterized by deposition of monosodium urate crystals in joints and other tissues. It affects 2% of adult men in Western countries [1] . These patients are also at risk for increased CV events (CVEs), as many of these patients have co-morbidities such as metabolic syndrome, hypertension and kidney disease [24] . Several studies have also demonstrated that gout is an independent risk factor for coronary heart disease [57] , heart failure [8], stroke [9] and mortality [10, 11] . This is thought to be the result of elevated serum uric acid (sUA). In the Third National Health and Nutrition Examination Survey with 15 773 participants, subjects with gout had 40% more CVEs and a 50% increase in mortality. A 1 mg/dl increase in sUA has been associated with a 28% increase in mortality [11] .
It has been hypothesized that urate-lowering therapy (ULT) can reduce CVEs [1214] . There are three major classes of ULTs. Uricosuric medications, such as probenecid, benzbromarone and sulfinpyrazone, increase renal uric acid secretion. The new sodiumglucose linked transporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus has similar properties [15] . Other medications, including angiotensin receptor blockers and fenofibrate, have been shown to have uricosuric properties as well [16, 17] . Xanthine oxidase inhibitors, such as allopurinol and febuxostat, reduce the production of uric acid [18] . Uricases catalyse the conversion of urate to more soluble degradation products. When initiating ULTs in patients with gout, there may be more gout attacks at first until a steady state is achieved, and since gout is a very inflammatory arthritis and is usually associated with elevated CRP and inflammation is prothrombotic, perhaps initial treatment with ULT increases CVEs. However, with longer use, perhaps the benefits of ULT in the reduction of gout events reduce CVEs in gout, where there is a clustering of other CV risk factors [2] .
We undertook our study to assess the relative CV safety of existing ULT. Our second goal was to identify any potential CV benefits or hazards associated with the lowering of sUA. Our primary safety endpoint was any CV death, non-fatal myocardial infarction or non-fatal stroke as included in the Anti-Platelet Trialists' Collaboration (APTC) composite endpoint [19] . Secondary endpoints were all-cause mortality and non-APTC CVE, including angina, transient ischaemic attack, arrhythmias, heart failure, cardiomyopathy and pulmonary/peripheral thromboembolism.
Methods

Inclusion criteria
Participants included for this review were adults (>18 years of age) with asymptomatic hyperuricaemia or the diagnosis of gout based on the preliminary or updated ACR criteria [20, 21] . Only randomized controlled trials (RCTs) in English were considered for inclusion. Eligible trials had to report CV safety of a ULT. Potential medications included allopurinol, febuxostat, pegloticase, rasburicase, probenecid, benzbromarone, sulphinpyrazone, losartan, fenofibrate and SGLT2 inhibitors. Any dosing regimen, follow-up duration and sample size was allowed. The comparator group could be placebo or another ULT. Studies evaluating non-ULTs in the setting of acute gout management or prophylaxis during the initiation of a ULT were excluded. If studies of losartan, fenofibrate or SGLT2 inhibitors were found and included, a subset analysis was planned to exclude those studies, as they have obvious other ways of decreasing CVE, such as lowering of blood pressure, cholesterol or glucose. Where possible, studies with asymptomatic uric acid were excluded in a subset analysis, as these patients would not have the acute inflammatory gout flares that raise CRP and may potentially increase CV risk.
Study selection
We performed the literature search using the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, PubMed and Scopus in February 2015 and again in October 2016. We used the following search terms and the results were limited to controlled trials: uric acid, gout, hyperuricaemia, gout suppressants, uricosuric agents, urate lowering therapy, xanthine oxidase inhibitors, allopurinol, febuxostat, probenecid, benzbromarone, sulfinpyrazone, angiotensin receptor antagonist, losartan, fenofibrate, SGLT2 inhibitors, uricase, pegloticase and rasburicase.
We also searched the ClinicalTrials.gov registry for unpublished trials. The abstract archives for ACR and EULAR meetings were also searched. Relevant references from included studies were sought to retrieve additional studies. Identified titles/abstracts were reviewed. Full texts were obtained if a study met all the inclusion criteria or there were uncertainties about the inclusion.
Data collection
Data from the studies were extracted by one reviewer (T.Z.) and ambiguities were resolved with the other reviewer (J.P.). We collected the following information on a standard data extraction form: author, year of publication, study location, follow-up duration, sample size, mean age, number of males, co-morbid conditions (CV diseases, diabetes, hyperlipidaemia, hypertension, obesity, smoking) and details related to our safety endpoints as outlined above.
If relevant details were insufficiently reported in studies, authors were contacted and the ClinicalTrials.gov register was searched to obtain further information.
Quality assessment
The methodological quality of each study was assessed using the Cochrane Collaboration's tool for assessing risk of bias [22] . It assesses for random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other sources of bias. Each item was rated as low, unclear or high risk of bias with supportive data from the study.
Statistical analysis
Data are presented as relative risk (RR) with 95% CIs. We performed meta-analyses using random-effects MantelHaenszel methods [23] . Subset analyses were done to explore the effects of the duration of follow-up.
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The I 2 statistic was used to quantify the magnitude of heterogeneity (mild, 030%; moderate, 3150%; high, >50%). Tau-squared was the square root of the between-study variance and P-values were for Cochrane's Q, the classic measure of heterogeneity. Forest plots and pooled estimates were reported. P-values <0.05 were considered statistically significant. Funnel plots were calculated to determine potential publication bias. Statistical tests and forest plots were determined using Review Manager version 5.3 (Nordic Cochrane Centre, Copenhagen, Denmark).
Results
Search results
We identified a total of 3084 citations with 642 duplicates. After the primary screen, 35 studies were selected for fulltext review. Six of these studies were not RCTs [17, 24, 2528] . One was a publication of the protocol for an ongoing study [29] , four were secondary analyses [3033] and eight other studies did not investigate the safety profile of ULTs [16, 17, 3439] . The remaining 16 studies described unique trials [4054] . Two additional studies were identified by searching ClinicalTrials.gov [55, 56] , resulting in 18 studies that were included in our meta-analysis ( Fig. 1 ). With respect to contacting authors/sponsors, usually no extra data were provided.
Description of the included studies and participants
The characteristics of included studies are summarized in Table 1 . All studies recruited patients with a diagnosis of gout and elevated sUA. Four studies also included additional patients with asymptomatic hyperuricaemia [4851] . A total of 7757 patients were included. Nine trials were based in North America with 6032 patients (78% of all participants) [40, 41, 43, 44, 47, 5254, 56, 57] . Six were from Asia with a recruitment of 1518 participants (20%) [4851, 54, 57] . Three were European studies with 207 patients (2%) [42, 45, 46] . The mean age was 52 years (range 4771). Men accounted for 93% (range 58100%) of the pooled population. Approximately half of the patients had at least one other CV risk factor, such as existing CV disease, diabetes, hypertension, obesity or smoking. The mean baseline sUA level was 9.7 mg/dl (577 mmol/l). The medical therapies studied were benzbromarone, probenecid, allopurinol, febuxostat, rasburicase and pegloticase. The median duration of follow-up was 16 weeks (range 2172).
Quality assessment
The risk of bias for each study is summarized in Fig. 2 . With respect to allocation, most trials described the appropriate use of random sequence generation and allocation concealment. However, seven studies did not provide details regarding the method of randomization aside from stating that it was a randomized trial [40, 43, 44, 48, 5456] . Blinding of participants and personnel (performance bias) and blinding of outcome assessment (detection bias) were evaluated. Four trials were deemed to have a risk of bias given a lack of blinding [4446, 48] . In assessing incomplete outcome data, four studies had either a high proportion of withdrawals [45, 54] , disproportionate withdrawals between different arms [44, 56] or a lack of rationale for withdrawals [54] . Lastly, one study was assessed to be at high risk for selective reporting bias, as it only reported adverse events that were undoubtedly related to the interventions [42] .
Primary safety endpoint
In evaluating relative CV safety among ULT in gout, eight studies compared febuxostat vs allopurinol (n = 6267 patients) [40, 43, 44, 47, 48, 50, 54, 57] (Fig. 3) . Four studies reported no APTC events in either intervention arm while the other four had 40 events in the febuxostat group (n = 3631) and 5 in allopurinol group (n = 1154 www.rheumatology.oxfordjournals.org each examining allopurinol vs rasburicase [42] , benzbromarone vs allopurinol [45] and benzbromarone vs probenecid [46] . No APTC events were reported in any of the three studies. . Two studies compared allopurinol and placebo, but no APTC events were reported in either group [43, 53] .
Of the four studies that included asymptomatic hyperuricaemia, only one had a reportable outcome. Katamani et al. [49] reported a non-fatal stroke in the febuxostat group, compared with no events in the placebo group. Excluding these studies did not significantly alter our results.
Subset analyses were done on studies comparing allopurinol vs febuxostat, placebo vs any ULT and placebo vs febuxostat. Comparing shorter studies (<52 weeks) to longer ones did not reveal any statistical differences. However, in long-term studies with febuxostat vs allopurinol, results were nearly significant, with more CVEs occurring with febuxostat treatment. [40, 43, 44, 47, 49, 50, 54, 57] . Almost half of these studies reported no events. Similarly, no safety endpoints of interest occurred in the studies examining allopurinol vs rasburicase [42] , benzbromarone vs allopurinol [45] and benzbromarone vs probenecid [46] .
Comparing any ULT to placebo, pooled results from eight studies (n = 2221) did not demonstrate a statistically significant difference in non-APTC events [any ULT vs placebo: RR [52] . No statistical differences in outcomes   FIG. 2 Risk of bias summary for uricosuric medications in randomized trials of gout and CVEs were noted between short-and long-term studies for non-APTC CVEs and mortality.
All statistical analyses were performed again using the Peto odds ratio to assess the robustness of our results [58] . The results were similar to our primary analysis. We did not note any discrepancies in the statistical significance of the results nor any changes in the direction of the effects. This sensitivity analysis was performed since there is no universally accepted optimal method for performing a meta-analysis to summarize studies with rare events.
Funnel plots assessing publication bias are shown in Fig. 4 . Some asymmetry was noted in the comparison of febuxostat vs allopurinol. However, given the limited number of studies included, no further testing was performed due to the high risk of type I error.
Discussion
Patients with gout are at inherently increased risk for CVEs due to co-morbid conditions, including inflammatory arthritis, often with very high inflammatory markers that could increase the acute or chronic risk of CVE, and perhaps due to elevated sUA. Our study is the first to summarize the best available evidence with regards to CV effects of existing ULT in gout (which was usually chronic or recurrent). We did not find any statistically significant differences in febuxostat vs allopurinol for CVEs. However, there may be a trend towards less favourable CV outcomes with febuxostat in an exploratory analysis of longer studies. In the long-term extension study EXCEL, enrolling 1086 patients for up to 40 months of follow-up, serious CVEs were reported in 4, 2 and 3% for febuxostat 80 mg, febuxostat 120 mg and allopurinol, respectively [44] . Ten subjects also died during the study, all of whom were in the febuxostat group, including six deaths attributed to CVEs. It was noted that many of these subjects had multiple CV risk factors and the events were not deemed by the investigators to be related to the study drug. In a subsequent trial, CVEs were noted to be comparable, at 0, 0.4 and 0.4% for febuxostat 40 mg, febuxostat 80 mg and allopurinol, respectively [47] . One death occurred in each febuxostat group and three in the allopurinol group. Of note, the follow-up duration was only 6 months, which was less than the EXCEL trial. Using the Food and Drug Administration adverse event reporting system up to the fourth quarter of 2011 from the drug's approval date, Gandhi et al. [59] identified potential signals of febuxostat-associated CV thrombo-emoblic events, with a total of 21 reports noted. Because of the uncertainty, two large RCTs are now under way. The CArdiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular ComoRbiditiES study compares the two xanthine oxidase inhibitors in approximately 7500 patients with planned follow-up of 5 years [29] . The Febuxostat vs Allopurinol Streamlined Trial, which is to be completed in the UK and Denmark, plans to randomize 5000 patients with at least 3 years of follow-up [60] . Both trials are designed to evaluate CVE specifically.
Independent of any drug effects, gout has been thought to be a risk factor by itself for CVE. Elevated sUA levels can cause endothelial dysfunction, platelet adhesiveness and production of pro-inflammatory substances, accelerating underlying CV diseases [3, 61, 62] . Lowering serum uric acid has been hypothesized to have the added benefits of CV protection. Allopurinol has been shown to reduce oxidative stress and delay the time to onset of angina [63] . Decreased CV mortality and heart failure readmissions have also been associated with allopurinol use in cohort studies [6466] . However, not all results are concordant. In a Taiwanese population-based matched-cohort study, 5000 patients 540 years of age were separated into allopurinol and non-allopurinol groups after matching for potential confounders such as age, sex and other CV risk factors. After a median of 5.25 years, the allopurinol group was found to have a moderate increase in CV risk (RR 1.20) [67] . However, despite matching, this was not an RCT and unknown confounders may have been present, such as confounding by indication (being prescribed allopurinol differentially in those with more severe CV risks). Another cohort study did not find any correlation between CV risk and initiation of xanthine oxidase inhibitors in gout patients [68] .
Our results did not demonstrate different CVE rates among allopurinol or febuxostat compared with placebo. No data were available for uricosuric medications. Pegloticase vs placebo in one trial showed a non-significant RR for CVEs over 25 weeks, where all 14 APTC and non-APTC CVEs were in the pegloticase group (n = 179) vs none in the placebo group (n = 46) [52] . In the subsequent extension study, all enrolled patients (n = 149) were assigned pegloticase biweekly or monthly. After a mean of 25 months, 24 CVEs occurred in 21 patients. Four deaths also occurred, with three related to sepsis and one secondary to underlying haematologic malignancy, but there was no comparison group [28] . A higher than expected CVE rate associated with pegloticase has been published, which could reflect the increased CV burden in patients with severe gout [69] .
There are limitations of this meta-analysis. Event rates were low and there was a highly variable length of followup and an accurate estimate of the CV protective effect from the reduction of recurrent gout attacks could take far longer to be seen, especially as there may be increased gout flares initially with reducing sUA. The heterogeneity of patient populations and study treatments represent another limitation. We were unable to explore any potential differences in CV effects that may exist among the different mechanisms of ULT due to the paucity of data associated with uricosurics and uricases in particular. The meta-analysis could be underpowered, as studies were not powered to study CVE. The collection of serious adverse events and how they were reported and interpreted may have varied per trial, but within any study the reporting inaccuracies should have been similar between treatment arms, so there is internal validity in the comparisons. Also, most major CVEs such as myocardial infarction, stroke and unstable angina would have resulted in hospitalization or death, so there is less likelihood that clinically relevant CVEs were missed. The generalizability of the data are unknown, as studyspecific inclusion and exclusion criteria eliminated patients with severe uncontrolled comorbidities and patients who were thought to be non-adherent. If there are long-term reductions in CVEs for the effective treatment of recurrent gout, we cannot necessarily differentiate changes in CVEs with lowering of inflammation or lowering sUA, or both. We did not study ULT in asymptomatic people and cannot comment on potential benefits or risks of ULT in that population. Meta-analysing trials studying rare adverse events that were obviously underpowered gives statistical concerns (underpowering or having no events in one group could cause an odds ratio of infinity). We used the Cochrane handbook and avoided inverse-variance methods and excluded studies with zero events [58] . We further assessed the robustness of our analysis with the Peto odds ratio, which did not change the overall interpretation of the results. Using a risk difference method can result in imprecise CIs, which could be a limitation of our study.
The strengths of the meta-analysis include that only RCTs were included, so within-study bias should be low. Subset analyses were done to explore potentially protective CV effects associated with the length of time on treatment.
Conclusions
Although patients with gout have an increased risk of CVEs, data from RCTs of ULTs do not show a reduction in CVEs compared with placebo. Due to the lack of data, the effect of uricosurics and uricases on CV outcomes is unclear. While the short-term CV safety of allopurinol and febuxostat is comparable, long-term data from ongoing trials will be helpful.
